SG11201506450RA - Tricyclic heterocycles as anticancer agents - Google Patents
Tricyclic heterocycles as anticancer agentsInfo
- Publication number
- SG11201506450RA SG11201506450RA SG11201506450RA SG11201506450RA SG11201506450RA SG 11201506450R A SG11201506450R A SG 11201506450RA SG 11201506450R A SG11201506450R A SG 11201506450RA SG 11201506450R A SG11201506450R A SG 11201506450RA SG 11201506450R A SG11201506450R A SG 11201506450RA
- Authority
- SG
- Singapore
- Prior art keywords
- anticancer agents
- tricyclic heterocycles
- tricyclic
- heterocycles
- anticancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766387P | 2013-02-19 | 2013-02-19 | |
| PCT/US2014/017127 WO2014130534A1 (en) | 2013-02-19 | 2014-02-19 | Tricyclic heterocycles as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201506450RA true SG11201506450RA (en) | 2015-09-29 |
Family
ID=51391756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506450RA SG11201506450RA (en) | 2013-02-19 | 2014-02-19 | Tricyclic heterocycles as anticancer agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9796717B2 (de) |
| EP (1) | EP2958565A4 (de) |
| JP (1) | JP2016508521A (de) |
| KR (1) | KR20150119390A (de) |
| CN (1) | CN105073117A (de) |
| AU (1) | AU2014219042A1 (de) |
| BR (1) | BR112015019818A2 (de) |
| CA (1) | CA2901493A1 (de) |
| IL (1) | IL240612A0 (de) |
| MX (1) | MX2015010407A (de) |
| RU (1) | RU2015139700A (de) |
| SG (1) | SG11201506450RA (de) |
| WO (1) | WO2014130534A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3116860B1 (de) | 2014-03-11 | 2018-02-07 | Icahn School of Medicine at Mount Sinai | Aus tricyclyl-2-aminocycloalkanolen abgeleitete sulfonamide als antikrebsmittel |
| US9937180B2 (en) | 2014-03-11 | 2018-04-10 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
| WO2017044567A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| WO2017044575A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| JP6955485B2 (ja) | 2015-09-09 | 2021-10-27 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| WO2023164940A1 (zh) * | 2022-03-04 | 2023-09-07 | 中国福利会国际和平妇幼保健院 | 氮杂吩噻嗪类化合物及其在制备治疗子宫内膜癌的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634766A (en) * | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
| GB8510680D0 (en) * | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| DE69431470T2 (de) | 1993-07-26 | 2003-08-14 | Eisai Co., Ltd. | Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring |
| WO1997030038A1 (fr) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Derives du diarylsultame |
| US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| ZA985218B (en) * | 1997-06-17 | 1998-12-15 | Schering Corp | Novel sulfonamide inhibitors of farnesyl-protein transferase |
| WO1999043683A1 (fr) * | 1998-02-27 | 1999-09-02 | Eisai Co., Ltd. | Derives de benzothiazine condense heterocyclique |
| AU2001291040A1 (en) * | 2000-09-20 | 2002-04-02 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| CA2599419A1 (en) | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| JP6105585B2 (ja) | 2011-08-16 | 2017-03-29 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗腫瘍剤としての三環式化合物 |
| EP2887803A4 (de) | 2012-08-24 | 2016-08-03 | Univ Texas | Pro-neurogene verbindungen |
| CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
| EP3116860B1 (de) | 2014-03-11 | 2018-02-07 | Icahn School of Medicine at Mount Sinai | Aus tricyclyl-2-aminocycloalkanolen abgeleitete sulfonamide als antikrebsmittel |
| US9937180B2 (en) | 2014-03-11 | 2018-04-10 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
-
2014
- 2014-02-19 CA CA2901493A patent/CA2901493A1/en not_active Abandoned
- 2014-02-19 EP EP14754200.5A patent/EP2958565A4/de not_active Withdrawn
- 2014-02-19 WO PCT/US2014/017127 patent/WO2014130534A1/en active Application Filing
- 2014-02-19 JP JP2015558219A patent/JP2016508521A/ja active Pending
- 2014-02-19 RU RU2015139700A patent/RU2015139700A/ru not_active Application Discontinuation
- 2014-02-19 CN CN201480009539.1A patent/CN105073117A/zh active Pending
- 2014-02-19 MX MX2015010407A patent/MX2015010407A/es unknown
- 2014-02-19 AU AU2014219042A patent/AU2014219042A1/en not_active Abandoned
- 2014-02-19 SG SG11201506450RA patent/SG11201506450RA/en unknown
- 2014-02-19 BR BR112015019818A patent/BR112015019818A2/pt not_active IP Right Cessation
- 2014-02-19 KR KR1020157025564A patent/KR20150119390A/ko not_active Application Discontinuation
- 2014-02-19 US US14/768,632 patent/US9796717B2/en active Active
-
2015
- 2015-08-17 IL IL240612A patent/IL240612A0/en unknown
-
2017
- 2017-09-19 US US15/708,916 patent/US20180002339A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015019818A2 (pt) | 2017-07-18 |
| IL240612A0 (en) | 2015-10-29 |
| CA2901493A1 (en) | 2014-08-28 |
| US9796717B2 (en) | 2017-10-24 |
| EP2958565A1 (de) | 2015-12-30 |
| JP2016508521A (ja) | 2016-03-22 |
| AU2014219042A1 (en) | 2015-09-17 |
| CN105073117A (zh) | 2015-11-18 |
| EP2958565A4 (de) | 2016-07-27 |
| US20150376191A1 (en) | 2015-12-31 |
| KR20150119390A (ko) | 2015-10-23 |
| RU2015139700A (ru) | 2017-03-27 |
| MX2015010407A (es) | 2015-10-26 |
| WO2014130534A1 (en) | 2014-08-28 |
| US20180002339A1 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210212T8 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| ZA201506880B (en) | Quinolines derivatives as novel anticancer agents | |
| HK1219939A1 (zh) | 三環苯並氧雜硼雜環戊烯化合物及其用途 | |
| IL243323A0 (en) | Anti-cancer combinations | |
| IL240612A0 (en) | Tricyclic heterocycles as anti-cancer agents | |
| PL3071578T3 (pl) | Tricykliczne związki piperydyny | |
| HK1222652A1 (zh) | 取代的三唑並吡啶類 | |
| HK1219728A1 (zh) | 新型抗瘧疾藥劑 | |
| GB201603522D0 (en) | Pyrazolochalcones as potential anticancer agents | |
| ZA201403137B (en) | Sock | |
| GB201300649D0 (en) | Cyclization | |
| GB201317949D0 (en) | Anticancer treatments | |
| GB201314504D0 (en) | Anticancer treatments |